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Background: To determine the diagnostic accuracy of a rapid heart-type fatty acid-binding protein (H-FABP)
test in patients suspected of acute coronary syndrome (ACS) in primary care.
Methods: General practitioners included 298 patients suspected of ACS. In all patients, whether referred to
hospital or not, ECG and cardiac biomarker testing was performed. ACS was determined in accordance
with international guidelines. Multivariate analysis was used to determine the value of H-FABP in addition
to clinical ﬁndings.
Results:Meanpatient agewas 66 years (SD 14), 52%was female and 66 patients (22%)were diagnosedwith ACS.
The H-FABP bedside test was performed within 24 h (median 3.1, IQR 1.5 to 7.1) after symptom onset. The
positive predictive value (PPV) of H-FABPwas 65% (95% conﬁdence interval (CI) 50–78). The negative predictive
value (NPV) was 85% (95% CI 80–88). Sensitivity was 39% (29–51%) and speciﬁcity 94% (90–96%). Within 6 h
after symptom onset, the PPV was 72% (55–84) and the NPV was 83% (77–88), sensitivity 43% (31–57%) and
speciﬁcity 94% (89–97%). Adding the H-FABP test to a diagnostic model for ACS led to an increase in the area
under the receiver operating curve from 0.66 (95% CI 0.58–0.73) to 0.75 (95% CI 0.68–0.82).
Conclusion: The H-FABP rapid test provides modest additional diagnostic certainty in primary care. It cannot be
used to safely exclude rule out ACS. The test can only beused safely in patients otherwiseNOT referred tohospital
by the GP, as an extra precaution not to miss ACS (‘rule in’).© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Early interventions aimed at restoring coronary blood ﬂow in pa-
tientswith acute coronary syndrome (ACS) reducesmyocardial damage
and improves patient outcome. Yet, a timely diagnosis can be a diagnos-
tic challenge for the clinician. In the majority of European countries, in-
cluding the Netherlands, many patients suspected of ACS – comprising
acute myocardial infarction (AMI) and unstable angina – will contact a
general practitioner (GP) ﬁrst. Typically, the GP will assess patients
suspected of ACS by history taking and physical examination. Using
these limited diagnostic tools, it is notoriously difﬁcult to accurately ex-
clude or conﬁrm ACS, notably in patients with atypical symptoms [1].
Additional diagnostic information such as electrocardiography (ECG)
is often not available in primary care, while ECGs taken early after the
onset of complaints will not always reveal the typical ST-segment6 5396 4456; fax: +31 88 756
.H.E. Bruins Slot).
Ltd. All rights reserved.elevation or Q-wave changes indicative of myocardial infarction [2].
Alternatively, plasma biomarkers of myocardial damage have shown
to be very accurate in detecting myocardial necrosis. Of these
biomarkers, troponin, which is typically elevated 6–9 h after the onset
of ischemia [3,2,4], has become an indispensable diagnostic tool in
the diagnosis of ACS. Most patients with symptoms suggestive of ACS,
however, present themselves to the GP as early as 1 and 3 h after
symptom onset [5–7]. Several uncertain hours therefore remain, in
which current troponin assays (including high-sensitive tests) cannot
provide the diagnostic certainty needed to accurately exclude or con-
ﬁrm ACS. This makes heart-type fatty acid-binding protein (H-FABP)
an interesting new biomarker, as it is released into the circulation
very rapidly after the onset of cardiac ischemia and elevated levels
have been detected already from 1 h onwards [8–10]. Especially in a
primary care setting, a bedside test for H-FABP, providing results within
15 min [11], could be a helpful diagnostic tool, but the accuracy of such
a test has not been assessed in primary care. Therefore, our aim in this
study was to determine the diagnostic accuracy, additional value in
combination with clinical ﬁndings and feasibility of a rapid H-FABP
bedside test in patients suspected of ACS in primary care.
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The design and methods of this study have been described extensively elsewhere
[12]. In short, all patients suspected of an acute coronary syndrome by the GP (e.g. pa-
tients presenting with chest pain, or other more ‘vague’ symptoms such as abdominal
discomfort or shortness of breath, prompting a GP to suspect ACS) were consecutively
included in three out-of-hours GP services in the Utrecht region (one urban and two
semi-urban). Additionally, 25 GPs from 9 group practices recruited patients during
daytime hours. We excluded patients with complaints lasting more than 24 h and
patients requiring instant hospital referral, as judged by the GP. Diagnostic assessment
during the initial GP consultation consisted of standardized history taking and physical
examination with performance of a blinded H-FABP bedside test. Only after making the
referral decision, the GP de-blinded the H-FABP test and recorded the test result on a
standardized case record form. The decision about hospital referral was thus made
in accordance with current daily practice, using only history taking and physical
examination and, when available, ECG. However, for safety reasons an exception was
made for patients with a positive H-FABP test result in whom the GP initially decided
not to refer. In these cases, the GP was instructed to change his initial management
decision in favour of hospital referral.
The study protocol was approved by the Medical Ethics Committee of the University
Medical Center Utrecht. All patients provided written consent. The authors of this
manuscript have certiﬁed that they comply with the Principles of Ethical Publishing in
the International Journal of Cardiology.
The H-FABP bedside test (Cardiodetect® Rennesens GmbH, Berlin) used in this
study is a rapid chromatographic immunotest designed for qualitative determination
of H-FABP in whole blood samples with a threshold of 7 ng/ml. It consists of a sample
pad (blood separator), a conjugate pad, a nitrocellulose membrane and an absorbent
pad incorporated in a test card that has the size of a credit card. Immobilized on the
membrane is a test line made of a speciﬁc capture monoclonal antibody for H-FABP
and a second line, acting as control, consisting of anti-mouse IgG. The test is performed
by drawing four drops of capillary whole blood from the patient's ﬁnger and applying
them onto the test-strip. Within 15 min the H-FABP test result (two red lines for
elevated plasma H-FABP and one red line for non-elevated plasma H-FABP) can be
read. For study purposes the test result was concealed by a blinding-strip. The
test was de-blinded by the GP after he/she had made the referral decision. The GP
documented the results on a standardized case report form, together with ﬁndings
from history taking and physical examination. Other items on the form included age,
gender and prior history of AMI or revascularisation (bypass surgery or percutaneous
coronary intervention).
In all patients, irrespective of whether they were referred to hospital or not, a
venous blood sample was collected between 12 and 36 h after onset of complaints,
for measurement of cardiac biomarkers (troponin, creatinin kinase (CK) and creatinin
kinase-myocardial band (CK-MB)). Also, we obtained a twelve-lead ECG in every
patient. In referred patients these measurements were performed as part of routine
care. Patients who were not referred to hospital were visited at home by qualiﬁed GP
laboratory service personnel for performance of these tests.
An expert panel consisting of two cardiologists and one GP established the ﬁnal
diagnosis in each patient. The panel used all available patient information, including
information from medical history taking and physical examination, ECG analysis,
biomarker levels, specialist letters and follow-up results up to one month after the
event (obtained by contacting the GPs of the patients). The expert panel was blinded
to the H-FABP rapid test results.
ACSwas deﬁned in accordancewith guidelines from the European Society of Cardiology
and theAmericanCollege of Cardiology [2,4]. The diagnosis of AMIwas establishedwhenpa-
tients had suggestive symptoms, e.g. chest pain, and a maximal concentration of troponin T
or I exceeding the decision limit, i.e., 99th percentile of the values for a reference control
group, within the ﬁrst 36 h after the onset of complaints, or CK-MB values greater than
two times the upper reference limit on at least one occasion during the same time frame,
or both. The presence of ST- and T-wave changes on the ECG, notably ST elevations
and Q-waves, could further conﬁrm AMI. Unstable angina was deﬁned as symptoms of
chest pain and ST- and/or T-wave changes on the ECG suggestive of ischemia, but without
elevation of troponin and CK-MB above the decision limits. When the diagnosis ACS or
unstable angina could not bemade, the panel identiﬁed themost likely alternative diagnosis
on the basis of the available information.
2.1. Data analysis
To evaluate the diagnostic value of the H-FABP test we constructed 2 by 2 tables with
the number of true positive (TP), false positive (FP), true negative (TN) and false negative
(FN) H-FABP test results and calculated positive and negative predictive values (PPV and
NPV) with 95% conﬁdence intervals. We used ACS as the primary outcome.
Using the multiple imputation function of SPSS version 17.0 (SPSS, Inc., Chicago Il,
USA) missing data, including unclear test results, were imputed. To determine whether
the H-FABP test provided added diagnostic value beyond the clinical parameters
obtained during history taking and physical examination, we performed multivariate
regression analysis with receiver operating characteristic (ROC) curves. We tested
two diagnostic models: in the ﬁrst one we only used an established clinical score
based on history taking (13); in the second one we combined the clinical score and
the H-FABP test result. The clinical score was previously used in a diagnostic model
for ACS by Grijseels et al. [13] and included radiation of chest pain, nausea/sweating,
the presence of prior cardiovascular disease and gender. The ability to discriminatebetween patients with and without ACS was studied with the area under the ROC
curve (AUC). We (internally) validated our models with bootstrapping techniques to
correct for over-optimism. The agreement between the observed proportions of ACS
and the risks predicted by the model, or calibration, was studied with a calibration plot.
3. Results
From March 2006 until September 2008, 336 consecutive patients
suspected by the GP of acute coronary syndrome were enrolled in the
study. We excluded 38 patients (11%). Of these, 12 refused informed
consent, 23 had symptoms suggestive of ACS for more than 24 h at
the time of testing, and three patients had an undetermined ﬁnal
diagnosis. These last three patients were not referred to a hospital
and, due to logistical problems, were not tested for cardiac biomarkers
and ECG at home. We could thus analyse the results of 298 patients
(Fig. 1, ﬂow diagram).
The mean age of participants was 66 years (SD 14) and 52% was
female. Most patients (n=209; 70%) presented themselves to the GP
within 6 h after onset of their complaints. The median duration from
the start of complaints until the performance of the H-FABP bedside
test was 3.1 (interquartile range (IQR) 1.5; 7.1) hours. Seventy-nine
percent of patients had one or more cardiovascular risk factor, while
36% of all patients had a history of cardiac disease (Table 1).
According to the panel 66 (22%) patients suffered an ACS. Of these
66 patients, 14 (21%) were classiﬁed as unstable angina, 18 (27%) as
ST-segment elevation myocardial infarction (STEMI) and 34 (52%) as
non ST-segment elevation myocardial infarction (NSTEMI). The 232
(78%) patients classiﬁed as non-ACS suffered from a variety of cardiac
and non-cardiac diseases. In 30 patients (13%) stable angina pectoris
was considered the alternative diagnosis. The most common non-
cardiac causes for the complaints were of gastro-intestinal origin
(gastric reﬂux in 16 patients, gall stones in 8 patients), and myalgia
(20 patients). In 106 (35%) patients the panel was unable to establish
an alternative explanation for the chest pain symptoms (Table 2).
Overall, 40 patients had a positive H-FABP test, and of these 26
suffered an ACS (PPV 65%, 95% CI 50–78%). Of the 258 patients with a
negative test, 218 did not suffer ACS (NPV 84%, 95% CI 80–88%). In a sub-
group analysis for women the overall PPV was 65% and the NPV was
88% while for patients over 65 years the PPV was 68% and the NPV
was 82% (Table 3, also giving results for sensitivity and speciﬁcity).
We separately analysed the results of the 209 (70%) patients who
presented to the GP within 6 h after the onset of symptoms. In this
0–6 time interval 32 patients had a positive H-FABP test and of
these, 23 suffered an ACS (PPV 72%, 95% CI 55–84%). Of the 177
patients with a negative test 147 did not suffer an ACS (NPV 83%, 95%
CI 77–88%) (Table 3, also giving results for sensitivity and speciﬁcity).
A subgroup analysis for women and patients over 65 years yielded
similar results (data not shown).
Two clinicalmultivariablemodel using only parameters fromhistory
taking had an area under the curve of 0.66 (95%CI: 0.58; 0.73). Adding
the result of the H-FABP test led to an AUC of 0.75 (0.68; 0.82) (Fig. 2).
We divided patients into three different risk categories for ACS
according to the diagnostic model: low risk (b15% chance of ACS,
n=75), intermediate risk (10–25%, n=146) and high risk (>25%,
n=76). In the low risk categories 43% of patients with a positive
test suffered from ACS and 91% of patients with a negative test did
not suffer from ACS. In the intermediate risk group PPV and NPV
were 60 and 87% respectively, while in the high risk group the PPV
was 85% and the NPV 73%.
3.1. Clinical feasibility of the bedside test
More than 50 GPs or supportive staff members of the out-of-hour
practices performed one or more tests. In 235 patients (79%) the test
result could be read within 15 min. In 63 patients (21%) there either
was an obvious test failure, or the GP was unsure about the
Fig. 1. Patient ﬂow diagram.
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was ‘unclear’. A second test was performed in 38 (60%) of these
patients, giving a test result for 29 (76%) patients. A deﬁnite test
failure or unclear test result remained in 34 (11%) cases.
4. Discussion
Our study is the ﬁrst to assess the diagnostic accuracy of an H-FABP
bedside test for acute coronary syndrome in a primary care setting. Of
the patients suspected by the GP, 22% was diagnosed with ACS. The
PPV of the H-FABP rapid test in our study was 65% and we found a
NPV of 85%. ROC curve analyses showed that when the H-FABP rapid
test was added to a clinical diagnostic score comprising radiation ofTable 1
Characteristics of 298 patients suspected of acute coronary syndrome, presenting to
the general practitioner.
Characteristics Number (%)
Age (mean, years) 66 (SD 14)
Male sex 143 (48)
History of AMI, bypass, PCI, angina pectoris 108 (36)
Presence of cardiovascular risk factorsa 236 (79)
Symptom duration at time of testing
(median in hours, IQR)
3.1 (1.5–7.1)
Referred to hospital 218 (73)
Positive H-FABP test 30 (10)
Inconclusive H-FABP test 34 (11)
Acute coronary syndrome 66 (22)
Unstable angina pectoris 14 (21)
Non ST-elevation Myocardial infarction 34 (52)
ST-elevation myocardial infarction 18 (27)
SD: standard deviation, AMI: acute myocardial infarction, PCI: primary coronary
intervention, IQR: interquartile range, and H-FABP: heart-type fatty acid-binding protein.
a Current smoker, diabetes, hypertension (documented in primary care or hospital
chart), and hypercholesterolemia.chest pain, nausea/sweating, prior cardiovascular disease and gender,
the area under the curve increased from 0.66 to 0.75, which indicates
that the rapid test improves diagnostic accuracy in addition to clinical
ﬁndings at presentation. In a subgroup of patients presenting within
6 h after the onset of complaints, results were similar.
Several studies investigating the diagnostic test properties of the
same bedside test that we used in our study (Cardiodetect©) have
yielded varying results. None of these studies were performed in a
primary care setting. In these studies the PPV ranged from 63 to 100%
and the NPV from 47 to 97% [14–19]. These results of previous studies
clearly show that there is uncertainty about the diagnostic properties
of the H-FABP rapid test. A direct comparisonwith our study is difﬁcult,
since our study is the ﬁrst to assess the diagnostic properties of theTable 2
Final diagnosis of participants as determined by outcome panel.
Final diagnosis Number (%)
Acute coronary syndrome 66 (22)
Unstable angina 14
Non ST-elevation myocardial infarction 34
ST-elevation myocardial infarction 18
Other cardiovascular diseases 51 (17)
Angina pectoris 30
Heart failure 3
Arrhythmias 15
Pericarditis 3
Noncardiovascular diseases 59 (20)
Myalgia 20
Anxiety/hyperventilation 11
Pulmonary embolism 4
Gall stones 8
Gastric reﬂux/ulcer 16
Other 16 (5)
Cause of complaints unknown 106 (36)
Table 3
Diagnostic accuracy of the H-FABP test per time interval with 95% conﬁdence interval
and original accuracy tables.
0–6 h 0–24 h
PPV 72 (55–84) 65 (50–78)
NPV 83 (77–88) 84 (80–88)
Sensitivity 43 (31–57) 39 (29–51)
Speciﬁcity 94 (89–97) 94 (90–96)
Likelihood + 7.5 (3.7–15.2) 6.53 (3.6–11.8)
Likelihood − 0.60 (0.47–0.76) 0.65 (0.53–0.79)
Accuracy tables 0–6 h ACS No ACS 0–24 h ACS No ACS
H-FABP + 23 9 H-FABP + 26 14
H-FABP − 30 147 H-FABP − 40 218
PPV: positive predictive value, NPV: negative predictive value, ACS: acute coronary
syndrome, H-FABP: heart-type fatty acid-binding protein.
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therefore be due to differences in patient domain, severity of disease,
variation in ACS prevalence (which ranged from 13-64% in the above
mentioned studies) and the amount of test failures (reported in only 2
studies [17,16], respective failure rate 14 and 17%). Also, nomultivariate
analysis was performed in these earlier studies. In addition, the added
value of the test (by comparing two diagnostic models, with and
without the H-FABP test) was not studied, while in daily practice such
a test will always be used in combination with other clinical tests,
typically history taking.
Our study shows that the H-FABP test can be of use for GPs, when
taking into account some important limitations. Using the test leads to
more diagnostic certainty in the diagnosis of ACS in patients suspected
of ACS, as was seen in the increased area under the ROC curve after
adding H-FABP to our diagnostic model for ACS. However, for a condi-
tion carrying a high morbidity and mortality such as ACS, the H-FABP
rapid test that we used in our study is by no means an ideal test.
For instance, a false negative test result was seen in 40/298 (13%) of
patients in our study, a percentage of ‘missed patients’ that is unaccept-
ably high. Therefore, in our opinion, the H-FABP test should not be usedFig. 2. Receiver operating characteristic (ROC) curve analysis with area under the curve (AU
parameters and H-FABP test result.for ruling out ACS. On the other hand, it could be used to provide more
diagnostic certainty in diagnosing ACS. Of the patients with a positive
test results, 65% have an ACS. Compared with a 22% a priori chance of
ACS, this is a substantial gain in diagnostic certainty. Moreover, when
used in the patient group considered at low risk for ACS (b15% chance
based on our diagnostic model with only clinical parameters, otherwise
not referred to hospital by the GP) still 43% of patients with a positive
test are diagnosed with ACS. When using this test, GPs will be able to
make a better informed referral decision in these low-risk patients by
referring patients with a positive H-FABP rapid test to a specialized
cardiologic intervention centre directly, instead of to a general hospital
that may lack these facilities. In patients that are considered by the GP
at an intermediate or high risk for ACS (requiring hospital referral)
however, theuse of f theH-FABP test cannot ne recommended. Anegative
test should not change the referral decision of the GP (false negatives),
and a positive test will also not change the management decision of
the GP: these patients should all be referred to hospital for additional
diagnostic testing and, if necessary, treatment.
The second aim of this study was to assess the feasibility of the
H-FABP rapid test. We found an initial unclear test result in 21% of
patients and after repeated testing, an unclear result remained in 11%.
This may partly be due to the set-up of our study in out-of-hour GP
practices, where many different GPs performed the test and many of
them performed a H-FABP test only once during the inclusion period.
Consequently, there was little learning effect for those GPs performing
the test. Also, the interpretation of the test result was dependent on
the subjective judgement of the coloured control line and H-FABP line
by the physician performing the test. This indicates that physicians
planning to use the bedside test in their daily practice should be well
informed on how to perform and read the test. To facilitate adequate
interpretation of the test an automated reading device that has now
become available could be of use.
Some limitations of our study should be discussed. Firstly, one could
argue whether we used the correct outcome in our study. According to
current guidelines, AMI is characterised by ischemia severe enough to
cause sufﬁcient myocardial damage to release detectable quantities ofC) and 95% CI for two diagnostic models. Model A: clinical parameters. Model B: clinical
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there is ischemia without a measurable amount of a cardiac biomarker
in the circulation [20,4]. We used ACS as the primary endpoint in this
study, because in primary care there is no difference in management
decision: both AMI and unstable angina patients should be referred to
hospital for further treatment. Previous studies suggest that H-FABP is
a very sensitive marker for even minor myocardial injury in patients
with unstable angina. Using ACS as primary outcome could therefore
lead to an underestimation of the diagnostic accuracy of H-FABP in
acute myocardial infarction, because the ischemia in unstable angina
detected by H-FABP will by deﬁnition not be detected by the reference
standard that we used (troponin). An analysis, taking acute MI as the
outcome yielded similar results, however. Secondly, as we already
mentioned, the H-FABP test was performed by many untrained GPs
and GP practice personnel, which probably led to the relatively high
number of unclear test results. Because we believe that in clinical
practice after proper training there will be less unclear test results, we
imputed the unclear test results.
An important strength of our study is that we performed this diag-
nostic accuracy study in a primary care setting, where improvement in
the early diagnosis of ACS is neededmost. Furthermore, we included a
large number of consecutive patients suspected of ACS without
adopting many exclusion criteria and thus the patient population in
our study will very likely resemble the actual patients for whom the
test is intended.
In conclusion, the H-FABP rapid test does provide additional
diagnostic certainty in suspected ACS patients in primary care when
added to general patient and symptom characteristics. Since the test
cannot safely rule out ACS, however, we only recommended its use in
suspected patients considered as low risk and otherwise not referred
to hospital by the GP. A need remains for more adequate testing
methods or alternative biomarkers for the detection of bothmyocardial
infarction and unstable angina. It is possible that high sensitive troponin
could ﬁll that gap, but although there currently are commercial point of
care tests available for high sensitive troponin, no studies have been
published to evaluate its clinical effectiveness.
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